Indicators of neuroprotection with galantamine
Author:
- 1 January 2005
- journal article
- review article
- Published by Elsevier in Brain Research Bulletin
- Vol. 64 (6) , 519-524
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- P1-316 Functional studies on brain levels and ache inhibition with galantamine and donepezil in rats, mice and rabbitsNeurobiology of Aging, 2004
- Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patientsNeurobiology of Disease, 2004
- Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptorsNeuropharmacology, 2004
- M1 Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future TherapyJournal of Molecular Neuroscience, 2003
- Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's diseaseAmyloid, 2003
- Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor miceProceedings of the National Academy of Sciences, 2002
- Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's diseaseNeuroscience Letters, 2001
- Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic miceProceedings of the National Academy of Sciences, 2000
- Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer DiseaseJAMA, 1999
- SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASEThe Lancet, 1976